The revised guidelines also will lead to more than $20 million in extra health care costs, the research shows.
FDA regulatory momentum includes priority review and breakthrough therapy designation for a potential first-in-class CHB ...
Chronic hepatitis B occurs when the body cannot eliminate the hepatitis B virus following an acute infection. Having chronic (or lifelong) hepatitis B can increase a person’s risk of developing ...
Phase 3 trial results demonstrate that bepirovirsen significantly increases the proportion of patients achieving functional cure compared with placebo.
Panel A shows the structure of HDV, which shares the hepatitis B surface antigen (HBsAg) envelope with hepatitis B virus. The virion contains a single-stranded, circular RNA genome of approximately ...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced the primary endpoint was met in the Phase 2b portion of the AZURE-1 study evaluating brelovitug, an ...
This undated electron microscope image made available by the U.S. National Institutes of Health in February 2020 shows the Novel Coronavirus SARS-CoV-2. NIAID-RML via AP A cancer patient with a ...
Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases. The company is dedicated to educating ...
Mirum Pharmaceuticals (NasdaqGM:MIRM) reported positive primary endpoint results from its Phase 2b AZURE-1 study of brelovitug in chronic hepatitis delta virus (HDV). The trial showed robust antiviral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results